Main areas of responsibility include developing the Regulatory strategy for the facility and for the HPTs that are to be manufactured at the Institute, and embedding a quality management system across the organisation. In addition, Dr. Wanjala’s responsibilities include supporting the CEO / DG in developing the corporate strategy for the organisation.
Dr. Wanjala has been seconded from Kenya Medical Research Institute.